Based upon all the results from the literature, administration of a‐PD‐L1 and a‐CTLA‐4 blockade combined with CSCs‐targeted CAR‐T cells may be an effective immunotherapeutic strategy for cancer patients. Here, CTLA4 is linked to cancer.